Global Human Hepatitis B Immunoglobulin market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Get access now!

Global Human Hepatitis B Immunoglobulin Market Trends and Opportunities 2025-31

The global Human Hepatitis B Immunoglobulin market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. Human hepatitis B immunoglobulin (HBIG) is a blood-derived product that contains antibodies against the hepatitis B virus (HBV). HBIG is used for both the prevention and treatment of hepatitis B infection. Here is an overview of the prospect for human hepatitis B immunoglobulin: 1. Prevention of hepatitis B transmission: HBIG is administered to individuals at high risk of HBV transmission, such as newborns from HBV-infected mothers, healthcare workers exposed to HBV-positive blood, and individuals who have had close contact with someone infected with HBV. It provides passive immunity by rapidly increasing antibody levels against HBV, reducing the risk of infection. 2. Post-exposure prophylaxis: HBIG can be given as part of post-exposure prophylaxis, especially for individuals who have recently been exposed to HBV and have not been vaccinated or who have low or no immune response to HBV vaccines. It provides immediate protection against HBV infection while the body mounts its immune response. 3. Treatment of acute hepatitis B: HBIG can be used in the treatment of acute hepatitis B infection, especially in cases with severe symptoms or complications. It helps to reduce viral replication, control the infection, and prevent further damage to the liver. HBIG may be used in combination with antiviral medications for optimal treatment outcomes. 4. Pre-transplant and post-transplant prophylaxis: HBIG is often used in individuals undergoing liver transplantation for HBV-related liver disease. Pre-transplant HBIG administration aims to reduce viral load and prevent HBV re-infection of the transplanted liver. Post-transplant HBIG is given to suppress viral replication and provide long-term protection against HBV recurrence. 5. Long-term prophylaxis for chronic hepatitis B: In some cases of chronic hepatitis B infection, long-term HBIG administration may be recommended to maintain protective levels of antibodies and prevent disease progression or reactivation. This is often combined with antiviral medications to achieve the best outcomes. 6. Safety and efficacy: HBIG is derived from blood plasma and undergoes rigorous screening and testing to ensure safety and efficacy. However, as with any blood-derived product, there may be a minimal risk of transmitting infectious agents. The benefits of HBIG in preventing or treating HBV infection usually outweigh the potential risks. 7. Ongoing research and development: Research is ongoing to improve the efficacy, safety, and convenience of HBIG administration. This includes the development of recombinant HBIG and alternative dosing regimens to reduce the volume and frequency of administration. Overall, the prospect for human hepatitis B immunoglobulin lies in its vital role in preventing HBV transmission, providing immediate protection after exposure, treating acute infection, and managing chronic hepatitis B. Continued research and development will further enhance the benefits and applicability of HBIG, ensuring improved outcomes for individuals at risk of or infected with HBV. Infinity Market Research newest research report, the Human Hepatitis B Immunoglobulin Industry Forecast looks at past sales and reviews total world Human Hepatitis B Immunoglobulin sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Hepatitis B Immunoglobulin sales for 2025 through 2031. With Human Hepatitis B Immunoglobulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Hepatitis B Immunoglobulin industry. This Insight Report provides a comprehensive analysis of the global Human Hepatitis B Immunoglobulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Hepatitis B Immunoglobulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Human Hepatitis B Immunoglobulin market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Hepatitis B Immunoglobulin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Hepatitis B Immunoglobulin. This report presents a comprehensive overview, market shares, and growth opportunities of Human Hepatitis B Immunoglobulin market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) &nbsp;&nbsp;&nbsp; 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) &nbsp;&nbsp;&nbsp; 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) Segmentation by Application: &nbsp;&nbsp;&nbsp; Hepatitis B Carrier &nbsp;&nbsp;&nbsp; Hepatitis B Close Contacts This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Baxter &nbsp;&nbsp;&nbsp; CSL &nbsp;&nbsp;&nbsp; Bayer &nbsp;&nbsp;&nbsp; Grifols &nbsp;&nbsp;&nbsp; Octapharma &nbsp;&nbsp;&nbsp; Shanghai RAAS &nbsp;&nbsp;&nbsp; Hualan Biological &nbsp;&nbsp;&nbsp; China Biologic &nbsp;&nbsp;&nbsp; Tiantan Biologic &nbsp;&nbsp;&nbsp; Shuanglin Bio-pharmacy &nbsp;&nbsp;&nbsp; Sichuan Yuanda Shuyang &nbsp;&nbsp;&nbsp; Boya Bio-pharmaceutical &nbsp;&nbsp;&nbsp; Shanghai Institute of Biological Key Questions Addressed in this Report What is the 10-year outlook for the global Human Hepatitis B Immunoglobulin market? What factors are driving Human Hepatitis B Immunoglobulin market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Human Hepatitis B Immunoglobulin market opportunities vary by end market size? How does Human Hepatitis B Immunoglobulin break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Human Hepatitis B Immunoglobulin Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Human Hepatitis B Immunoglobulin by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Human Hepatitis B Immunoglobulin by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Human Hepatitis B Immunoglobulin Segment by Type &nbsp;2.2.1 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) &nbsp;2.2.2 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) &nbsp;2.2.3 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) &nbsp;2.3 Human Hepatitis B Immunoglobulin Sales by Type &nbsp;2.3.1 Global Human Hepatitis B Immunoglobulin Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Human Hepatitis B Immunoglobulin Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Human Hepatitis B Immunoglobulin Sale Price by Type (2020-2025) &nbsp;2.4 Human Hepatitis B Immunoglobulin Segment by Application &nbsp;2.4.1 Hepatitis B Carrier &nbsp;2.4.2 Hepatitis B Close Contacts &nbsp;2.5 Human Hepatitis B Immunoglobulin Sales by Application &nbsp;2.5.1 Global Human Hepatitis B Immunoglobulin Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Human Hepatitis B Immunoglobulin Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Human Hepatitis B Immunoglobulin Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Human Hepatitis B Immunoglobulin Breakdown Data by Company &nbsp;3.1.1 Global Human Hepatitis B Immunoglobulin Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Human Hepatitis B Immunoglobulin Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Human Hepatitis B Immunoglobulin Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Human Hepatitis B Immunoglobulin Revenue by Company (2020-2025) &nbsp;3.2.2 Global Human Hepatitis B Immunoglobulin Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Human Hepatitis B Immunoglobulin Sale Price by Company &nbsp;3.4 Key Manufacturers Human Hepatitis B Immunoglobulin Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Human Hepatitis B Immunoglobulin Product Location Distribution &nbsp;3.4.2 Players Human Hepatitis B Immunoglobulin Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Human Hepatitis B Immunoglobulin by Geographic Region &nbsp;4.1 World Historic Human Hepatitis B Immunoglobulin Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Human Hepatitis B Immunoglobulin Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Human Hepatitis B Immunoglobulin Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Human Hepatitis B Immunoglobulin Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Human Hepatitis B Immunoglobulin Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Human Hepatitis B Immunoglobulin Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Human Hepatitis B Immunoglobulin Sales Growth &nbsp;4.4 APAC Human Hepatitis B Immunoglobulin Sales Growth &nbsp;4.5 Europe Human Hepatitis B Immunoglobulin Sales Growth &nbsp;4.6 Middle East & Africa Human Hepatitis B Immunoglobulin Sales Growth 5 Americas &nbsp;5.1 Americas Human Hepatitis B Immunoglobulin Sales by Country &nbsp;5.1.1 Americas Human Hepatitis B Immunoglobulin Sales by Country (2020-2025) &nbsp;5.1.2 Americas Human Hepatitis B Immunoglobulin Revenue by Country (2020-2025) &nbsp;5.2 Americas Human Hepatitis B Immunoglobulin Sales by Type (2020-2025) &nbsp;5.3 Americas Human Hepatitis B Immunoglobulin Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Human Hepatitis B Immunoglobulin Sales by Region &nbsp;6.1.1 APAC Human Hepatitis B Immunoglobulin Sales by Region (2020-2025) &nbsp;6.1.2 APAC Human Hepatitis B Immunoglobulin Revenue by Region (2020-2025) &nbsp;6.2 APAC Human Hepatitis B Immunoglobulin Sales by Type (2020-2025) &nbsp;6.3 APAC Human Hepatitis B Immunoglobulin Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Human Hepatitis B Immunoglobulin by Country &nbsp;7.1.1 Europe Human Hepatitis B Immunoglobulin Sales by Country (2020-2025) &nbsp;7.1.2 Europe Human Hepatitis B Immunoglobulin Revenue by Country (2020-2025) &nbsp;7.2 Europe Human Hepatitis B Immunoglobulin Sales by Type (2020-2025) &nbsp;7.3 Europe Human Hepatitis B Immunoglobulin Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Human Hepatitis B Immunoglobulin by Country &nbsp;8.1.1 Middle East & Africa Human Hepatitis B Immunoglobulin Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Human Hepatitis B Immunoglobulin Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Human Hepatitis B Immunoglobulin Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Human Hepatitis B Immunoglobulin Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Human Hepatitis B Immunoglobulin &nbsp;10.3 Manufacturing Process Analysis of Human Hepatitis B Immunoglobulin &nbsp;10.4 Industry Chain Structure of Human Hepatitis B Immunoglobulin 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Human Hepatitis B Immunoglobulin Distributors &nbsp;11.3 Human Hepatitis B Immunoglobulin Customer 12 World Forecast Review for Human Hepatitis B Immunoglobulin by Geographic Region &nbsp;12.1 Global Human Hepatitis B Immunoglobulin Market Size Forecast by Region &nbsp;12.1.1 Global Human Hepatitis B Immunoglobulin Forecast by Region (2026-2031) &nbsp;12.1.2 Global Human Hepatitis B Immunoglobulin Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Human Hepatitis B Immunoglobulin Forecast by Type (2026-2031) &nbsp;12.7 Global Human Hepatitis B Immunoglobulin Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Baxter &nbsp;13.1.1 Baxter Company Information &nbsp;13.1.2 Baxter Human Hepatitis B Immunoglobulin Product Portfolios and Specifications &nbsp;13.1.3 Baxter Human Hepatitis B Immunoglobulin Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Baxter Main Business Overview &nbsp;13.1.5 Baxter Latest Developments &nbsp;13.2 CSL &nbsp;13.2.1 CSL Company Information &nbsp;13.2.2 CSL Human Hepatitis B Immunoglobulin Product Portfolios and Specifications &nbsp;13.2.3 CSL Human Hepatitis B Immunoglobulin Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 CSL Main Business Overview &nbsp;13.2.5 CSL Latest Developments &nbsp;13.3 Bayer &nbsp;13.3.1 Bayer Company Information &nbsp;13.3.2 Bayer Human Hepatitis B Immunoglobulin Product Portfolios and Specifications &nbsp;13.3.3 Bayer Human Hepatitis B Immunoglobulin Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Bayer Main Business Overview &nbsp;13.3.5 Bayer Latest Developments &nbsp;13.4 Grifols &nbsp;13.4.1 Grifols Company Information &nbsp;13.4.2 Grifols Human Hepatitis B Immunoglobulin Product Portfolios and Specifications &nbsp;13.4.3 Grifols Human Hepatitis B Immunoglobulin Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Grifols Main Business Overview &nbsp;13.4.5 Grifols Latest Developments &nbsp;13.5 Octapharma &nbsp;13.5.1 Octapharma Company Information &nbsp;13.5.2 Octapharma Human Hepatitis B Immunoglobulin Product Portfolios and Specifications &nbsp;13.5.3 Octapharma Human Hepatitis B Immunoglobulin Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Octapharma Main Business Overview &nbsp;13.5.5 Octapharma Latest Developments &nbsp;13.6 Shanghai RAAS &nbsp;13.6.1 Shanghai RAAS Company Information &nbsp;13.6.2 Shanghai RAAS Human Hepatitis B Immunoglobulin Product Portfolios and Specifications &nbsp;13.6.3 Shanghai RAAS Human Hepatitis B Immunoglobulin Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Shanghai RAAS Main Business Overview &nbsp;13.6.5 Shanghai RAAS Latest Developments &nbsp;13.7 Hualan Biological &nbsp;13.7.1 Hualan Biological Company Information &nbsp;13.7.2 Hualan Biological Human Hepatitis B Immunoglobulin Product Portfolios and Specifications &nbsp;13.7.3 Hualan Biological Human Hepatitis B Immunoglobulin Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Hualan Biological Main Business Overview &nbsp;13.7.5 Hualan Biological Latest Developments &nbsp;13.8 China Biologic &nbsp;13.8.1 China Biologic Company Information &nbsp;13.8.2 China Biologic Human Hepatitis B Immunoglobulin Product Portfolios and Specifications &nbsp;13.8.3 China Biologic Human Hepatitis B Immunoglobulin Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 China Biologic Main Business Overview &nbsp;13.8.5 China Biologic Latest Developments &nbsp;13.9 Tiantan Biologic &nbsp;13.9.1 Tiantan Biologic Company Information &nbsp;13.9.2 Tiantan Biologic Human Hepatitis B Immunoglobulin Product Portfolios and Specifications &nbsp;13.9.3 Tiantan Biologic Human Hepatitis B Immunoglobulin Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Tiantan Biologic Main Business Overview &nbsp;13.9.5 Tiantan Biologic Latest Developments &nbsp;13.10 Shuanglin Bio-pharmacy &nbsp;13.10.1 Shuanglin Bio-pharmacy Company Information &nbsp;13.10.2 Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Product Portfolios and Specifications &nbsp;13.10.3 Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Shuanglin Bio-pharmacy Main Business Overview &nbsp;13.10.5 Shuanglin Bio-pharmacy Latest Developments &nbsp;13.11 Sichuan Yuanda Shuyang &nbsp;13.11.1 Sichuan Yuanda Shuyang Company Information &nbsp;13.11.2 Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Product Portfolios and Specifications &nbsp;13.11.3 Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Sichuan Yuanda Shuyang Main Business Overview &nbsp;13.11.5 Sichuan Yuanda Shuyang Latest Developments &nbsp;13.12 Boya Bio-pharmaceutical &nbsp;13.12.1 Boya Bio-pharmaceutical Company Information &nbsp;13.12.2 Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Product Portfolios and Specifications &nbsp;13.12.3 Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Boya Bio-pharmaceutical Main Business Overview &nbsp;13.12.5 Boya Bio-pharmaceutical Latest Developments &nbsp;13.13 Shanghai Institute of Biological &nbsp;13.13.1 Shanghai Institute of Biological Company Information &nbsp;13.13.2 Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Product Portfolios and Specifications &nbsp;13.13.3 Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Shanghai Institute of Biological Main Business Overview &nbsp;13.13.5 Shanghai Institute of Biological Latest Developments 14 Research Findings and Conclusion

Report	Global Human Hepatitis B Immunoglobulin Market Growth 2025-2031
Selected License	Multi ID: LPI21378

Buyer Information

Order Summary